P22 virus-like particles displaying peptide antigens produced powerful antibody and killer T-cell responses that significantly inhibited tumor growth in mice.
Antibody titer of 5 × 10⁵VLP-displayed peptide antigens induced extremely high antibody responses, demonstrating the platform's ability to amplify immune recognition of small peptide fragments.
What the researchers found
P22 virus-like particles displaying B-cell epitope peptides (VLP-OVAB) induced antibody titers as high as 5.0 × 10⁵ against the peptide antigen. VLPs displaying T-cell epitope peptides (VLP-OVAT) induced highly effective cross-presentation and strongly activated cytotoxic T lymphocyte (CTL) responses.
In mouse tumor models, VLP-OVAT significantly inhibited tumor growth by increasing proportions of CD4+ T cells, CD8+ T cells, and effector memory T cells (TEM) among tumor-infiltrating lymphocytes while lowering the proportion of myeloid-derived suppressor cells (MDSCs) that help tumors evade the immune system.
Why it matters
Personalized cancer vaccines need to efficiently deliver neoantigen peptides to trigger strong immune responses, but current delivery methods often produce weak T-cell activation. VLPs offer a promising platform because they naturally stimulate the immune system, have a defined structure, and are biocompatible — potentially providing a standardized way to create individualized cancer vaccines based on each patient's tumor mutations.
The numbers in context
VLP-OVAB: Ab titer 5×10^5; VLP-OVAT: strong CTL activation; significant tumor inhibition; increased CD4+/CD8+/TEM; reduced MDSCs
How the study worked
Researchers genetically fused ovalbumin B-cell and T-cell epitope peptides to the coat protein of P22 bacteriophage, creating two types of virus-like particles (VLP-OVAB and VLP-OVAT). They measured antibody responses, cross-presentation efficiency, and CTL activation in vitro. Therapeutic efficacy was tested in mouse tumor models, with analysis of tumor growth rates and immune cell profiling of tumor-infiltrating lymphocytes and splenocytes.
Who was studied
Mice with OVA-expressing tumors
What this study cannot tell us
The study used ovalbumin as a model antigen rather than actual tumor neoantigens, so it remains unclear how well this platform would work with real patient-specific mutations. All experiments were conducted in mice, and the immune environment in human tumors is considerably more complex. Long-term safety data and manufacturing scalability for personalized VLP vaccines were not addressed.
How to read the evidence
This is a preclinical animal study using model antigens rather than actual tumor neoantigens. While the results are promising and the immune profiling is thorough, translation to human clinical applications requires significant additional validation.
When this study was published
Published in 2021, this study represents an active area of cancer vaccine research. The VLP platform approach has continued to develop since publication, with the field moving toward clinical translation of neoantigen vaccines.
The bigger picture
Neoantigen-based cancer vaccines are one of the most promising frontiers in immunotherapy, but delivering peptide antigens effectively remains a major challenge. This study demonstrates that VLPs — particularly from bacteriophage P22 — can serve as a versatile platform for displaying peptide antigens and generating both antibody and killer T-cell responses. If this translates to human neoantigens, it could accelerate the development of personalized cancer immunotherapies.
Questions still open
- Can this P22 VLP platform effectively display and deliver actual tumor neoantigen peptides with the same immune activation seen with model antigens?
- How does VLP-based peptide vaccine efficacy compare to mRNA or dendritic cell approaches for neoantigen delivery?
- What is the manufacturing timeline for creating personalized P22 VLP vaccines for individual patients?
Common questions
What are virus-like particles and why are they used for vaccines?
How could this technology lead to personalized cancer vaccines?
Read the original research
P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy.
Biomaterials, 271, 120726
Citation
Li, Wenjing; Jing, Zhe; Wang, Shuqing; Li, Qiyu; Xing, Yutong; Shi, Haobo; Li, Shuang; Hong, Zhangyong. (2021). P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy.. Biomaterials, 271, 120726. https://doi.org/10.1016/j.biomaterials.2021.120726